Did markets hit a turning point? The past couple of months brought us a seven-week losing streak in stocks, the longest such streak in over a decade, but the week before the Memorial Day holiday weekend saw strong gains. The S&P 500 wiped out its May losses. Post-holiday trading shows that some of these gains are continuing.
If so, then it makes this the ideal time to buy the dip, to get in while stocks remain at low cost, with attractive entry points. Thats the view from investment firm JPMorgan, where Dubravko Lakos-Bujas of the equity macro research group tries to bring some clarity from the overall situation. Lakos-Bujas points out that certain sectors notably small-caps, defensive stocks, and biotechs are likely to benefit most from this dynamic, and writes, Biotech is one of the most attractive on valuation while Pharma is also trading at cheapest level in a decade.
These are bright spots in an otherwise dark picture, but they do point to a way forward for investors willing to shoulder the risk. The stock analysts at JPM are following that path, finding stocks in Lakos-Bujas favored sectors that feature cheap valuations. Weve opened up the TipRanks database to pull up the details on two such picks; heres a closer look.
Penumbra (PEN)
Stroke, aneurysms, and embolisms are dangerous conditions with a common denominator: damage or blockage of the vascular system. Penumbra is a medical device company specializing in this field, offering a line of devices for the treatment of strokes and other vascular-related conditions. The companys devices are used in the treatment of acute ischemic stroke, brain aneurysms, and deep vein thrombosis, among others.
Penumbras leading device is the Indigo Aspiration System, for use in vascular thrombectomy. Indigo is described as having had a significant impact on its US patient base; the device is designed to remove blood clots in the peripheral arterial and venous systems, and to treat pulmonary embolisms, with minimal bleeding and blood loss.
Story continues
The company announced in April that the Indigo system has now been launched in Europe. The opening of a European market is an important expansion for Penumbra. Currently the companys US base accounts for 71% of total revenue. That top line reached $203.9 million in 1Q22, a gain of 20% over the year-ago total. Sales of vascular products accounted for $122.8 million of the total, while the companys neuro products used in treating the vascular system of the head and brain brought in $81.1 million. Penumbra is preparing release of its latest system, Thunderbolt, which is expected next year.
Analyst Robbie Marcus, covering PEN for JPMorgan, sees reason for optimism on this stock. He writes, We feel incrementally more positive on the longer-term outlook given the strong early reception for Thunderbolt and progress made building out the Real VR platform, and see a high probability of accelerating growth in 2023. Along with healthy trends in Peripheral, we think this all supports an attractive long-term growth outlook... We view todays valuation as an attractive entry point into a multi-year growth story driven by leadership in a diverse set of highly attractive end markets.
Everything that PEN has going for it prompted Marcus to rate the stock an Overweight (i.e. Buy). The cherry on top? His $245 price target implies ~74% upside from current levels. (To watch Marcus track record, click here)
Overall, this medical device firm has picked up 6 reviews from the Wall Street analysts in recent weeks, and these include 5 Buys against a single Hold for a Strong Buy consensus rating. The shares are priced at $140 and their $250.40 average price target suggests a one-year upside of 78%. (See PEN stock forecast on TipRanks)
Rocket Pharmaceuticals (RCKT)
From medical devices well move on to the cutting edge of biopharma tech, gene therapy, and look at Rocket Pharmaceuticals. This clinical-stage firm is a leader in the gene therapy field, developing novel treatments for severe disease conditions with high unmet medical needs. Gene therapies adapt various viruses as delivery systems to insert genetic information directly into disease-affected cells, altering the condition at the genetic and molecular levels. These therapies offer the potential to cure, and not just to treat, the targeted diseases.
Rocket has an active research program, featuring gene therapies that target several pediatric conditions and terminal cancers, such as Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency (LAD-I), and Pyruvate Kinase Deficiency (PKD). Rockets research program uses both associated viral vector (AAV) andlentiviralvector (LVV)platforms to deliver the therapeutic agents.
Rocket has four programs currently undergoing human clinical trials. The most advanced of these is the LAD-I track, studying drug candidate RP-L201. In May, Rocket presented top line data from the Phase 2 pivotal trial, showing that RP-L201 was well-tolerated by all patients in the trial and demonstrated a 100% survival rate one year after the drug infusion. All patients showed a clinical reversal of the disease course. Based on these findings, Rocket is planning to continue with regulatory filings in 1H23.
Also in May, Rocket released updates on its other three clinical tracks. RP-L102, a treatment for Fanconi Anemia, is at the Phase 2 pivotal stage and the clinical trial is underway. Top line data is expected for release in 3Q22. RP-A501, a treatment for Danon Disease, is also undergoing an active clinical trial, at Phase 1. The company is on schedule to release the pediatric patient cohort data during the third quarter of this year, and to initiate the pivotal Phase 2 trial in Q4. Finally, the PKD track, for RP-L301 in the treatment of Pyruvate Kinase Deficiency, is also progressing as anticipated. This trial is expected to release preliminary Phase 1 data during 4Q22, and at the same time to initiate activity in a Phase 2 pivotal trial.
All of this gives Rocket Pharmaceuticals an enviable position for any biopharma researcher: these many shots on goal provide plenty of potential for the company to deliver, even in a field as difficult as biopharmaceuticals.
JPMorgan analyst Eric Joseph looked under the hood of RP-L201 and wrote: RP-L201 treated patients also showed a significant reduction in prolonged hospitalization or severe infections relative to pre-treatment event rates, amounting to a meaningful improvement in their disease prognosis. There were no surprises on safety, with an overall well-tolerated profile consistent with earlier updates, seeing this drug candidate as the main driver for the company.
Joseph went on to add, about Rockets overall position: Along these lines, in view of multiple clinical readouts on track within 2022, including Danon pediatric efficacy data in 3Q22, we see current share levels as an attractive entry point to capture longer-term pipeline potential.
This reinforces the analyst's view that Rocket is a stock to "buy," and worth a $67 target price. At current levels, this target suggests a robust 462% upside for the coming year. (To watch Josephs track record, click here)
Some companies show a singularly strong outlook, and that can be seen when Wall Streets analysts who dont always agree come down unanimously in favor of a stock. RCKT has 9 recent positive analyst reviews, for a Strong Buy consensus rating. The shares are selling for $12.01 and have an average price target of $64.40, indicating a 12-month upside potential of 436%. (See RCKT stock forecast on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Visit link:
J.P. Morgan Sees an Attractive Entry Point in These 2 Stocks - Yahoo Finance
- 7 Social Security Shakeups You Need To Be Ready For Heading Into the New Year - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Crypto had a surprisingly great year. It still faces threats in 2024. - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- 'How the hell does that even happen?' McCarthy exits Congress amid confusion over who can run to replace him - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Short sellers lost close to $178 billion in 2023 - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Trump legal news brief: Giuliani files for bankruptcy after judge rules he must immediately pay $148 million for election ... - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- No One Wants Used EVs, Making New Ones a Tougher Sell Too - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Israel's military campaign in Gaza seen as among the most destructive in recent history, experts say - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Barbara Corcoran Says Housing Prices 'Are Going To Go Through the Roof' But When? - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Are You Wealthy? The Net Worth You Need To Be Considered Poor, Middle-Class And Wealthy In America - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- German bishop Btzing criticizes pope over Ukraine and Israel stance - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- 'Severe revenue decline': California faces a record $68 billion deficit here's what is eating away at the Golden State's ... - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Poll: Trump is tied with Biden for now but criminal trials and unpopular plans pose risks for 2024 - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Rudy Giuliani files for bankruptcy days after being ordered to pay $148 million in defamation case - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- 'It's just bragging rights': Once you achieve this credit score there's 'no benefit' to scoring higher, expert says here are ... - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Records released by House Republicans show that Joe Biden repeatedly emailed Hunter Biden's business associate ... - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Tesla Getting Trounced by S&P 500 Three Years After Joining - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Ukrainian forces shoot down three Russian Su-34 fighter jets on southern front - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- The only AI 'regulation' coming is from workers - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Innocent Black Man Spent 50 Years in Prison, His Compensation Will Annoy The Hell out of You - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Texas begins flying migrants from southern border to Chicago. The 1st plane carried over 120 people - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- Donald Trump Is Running Scared - Yahoo News - December 22nd, 2023 [December 22nd, 2023]
- The biggest 2024 threat to Big Tech is coming from both sides of the Atlantic - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- Apple halts online sales of its Apple Watch Series 9 and Apple Watch Ultra 2 - Yahoo Finance - December 22nd, 2023 [December 22nd, 2023]
- 2023 FIBA World Cup: Jaren Jackson Jr.'s elite rim protection and defensive presence come with a price - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Fantasy Football Rankings: These are the hardest players to ... - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Cowboys QB Dak Prescott feels for Will Grier after Trey Lance deal, not worried about future in Dallas - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Massive alligator captured in Mississippi is a new state record. Nightmare material - Yahoo! Voices - August 28th, 2023 [August 28th, 2023]
- Virginia Gov. Youngkin eyes a 15-week abortion ban as a 'consensus' voters would back - Yahoo News - August 28th, 2023 [August 28th, 2023]
- Poll: Trump could be in big trouble for 2024 if convicted of crimes - Yahoo News - August 28th, 2023 [August 28th, 2023]
- 'She-Hulk' star Tatiana Maslany nearly brought to tears after overcoming fears of heights and cold with the help of Bear Grylls - Yahoo Entertainment - August 28th, 2023 [August 28th, 2023]
- Don't feel guilty about being lazy. Experts say there are some health benefits. - Yahoo Life - August 28th, 2023 [August 28th, 2023]
- Center Paolo Banchero helps Team USA power past physical New Zealand in FIBA World Cup - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Tyreek Hill says Tua's response to ESPN criticism 'fires me up,' shows Dolphins something they've never seen - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- USA's Katie Moon, Australia's Nina Kennedy agree to share pole vault gold after tie atop World Athletics Championships - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Blue Jays' Bo Bichette, Matt Chapman leave game vs. Guardians with injuries - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Benches clear twice as Rays roll past Yankees 7-4: 'It's a last-place team' - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- All-Pro Chris Jones says hes willing to extend Chiefs holdout through Week 8 - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Fyre Festival II: Andy King confirms he's working with Billy McFarland for 'redemption'; 1st drop sells out - Yahoo Entertainment - August 28th, 2023 [August 28th, 2023]
- Pirates first overall pick Paul Skenes doesn't make it out of 1st inning in Double-A debut - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- U.S. men and women sweep gold in 4x100m relay at World Championships - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Spain soccer president Luis Rubiales apologizes for kissing player, as calls for his resignation mount - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- COVID cases are rising. What are schools doing about it? - Yahoo Life - August 28th, 2023 [August 28th, 2023]
- Nicolas Batum ashamed and scared to go home after France is knocked out of FIBA World Cup - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- Tour Championship: How much did Viktor Hovland, others earn at East Lake? - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- The Daily Sweat: Cubs get chance to cut into streaking Brewers' NL Central lead - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- NASCAR: Chris Buescher wins at Daytona after Ryan Preece's car flips at least 10 times in terrifying crash - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- With college sports more in flux than ever before, new players association group emerges - Yahoo Sports - August 28th, 2023 [August 28th, 2023]
- NFL Hall of Fame Game: How to watch the 2023 NFL preseason opener - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- 2023 NFL preseason: How to watch, full schedule, streaming info and more - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Reports: Colts considering placing Jonathan Taylor on NFI list, which could negate his 2023 salary - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Sources: Michigan's Jim Harbaugh, NCAA working toward 4-game suspension over recruiting investigation - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Oregon coach Dan Lanning slams Colorado after move to Big 12: I dont remember them winning anything - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- As Bethenny Frankel calls for reality show performers to strike, 'Below Deck' star Captain Lee is only partly on board - Yahoo Entertainment - July 31st, 2023 [July 31st, 2023]
- Ken Riley, Bengals' all-time INT leader, finally gets his flowers ... - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Broncos WR K.J. Hamler shares pericarditis diagnosis, will reportedly be waived with eye for return - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Sexist remarks from radio host enable Commanders to set tone that things are different after Dan Snyder - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Fantasy Football: What is the correct way to draft from these muddy NFL RB committees? - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Yahoo boys on rampage: The youth and Internet scam - Guardian Nigeria - July 31st, 2023 [July 31st, 2023]
- NFL training camp tracker: WR Tim Patrick carted off at practice, Broncos fear Achilles injury - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Is winning the lottery all it's cracked up to be? - Yahoo News - July 31st, 2023 [July 31st, 2023]
- Fantasy Football: How to avoid the most common draft mistakes in 2023 - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- 2023 Hall of Fame: Don Coryell's offense changed the NFL, even if it didn't win a Super Bowl - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Giants' pass-catchers are wielding uncertainty to their advantage - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- The USWNT diagnosed their biggest flaw in Dutch draw. Can they fix it? - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- Julius Erving's all-time top 10 includes Tiny Archibald, no active players - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- How to watch the Women's World Cup 2023: Full broadcast schedule, streaming info and more - Yahoo Sports - July 31st, 2023 [July 31st, 2023]
- 'Love Is Blind' star Deepti Vempati didn't talk about her eating disorder with family growing up: 'I used to live this double life' - Yahoo Life - March 4th, 2023 [March 4th, 2023]
- Ja Morant reportedly accused of repeatedly punching teenage boy in head, threatening him with gun last summer - Yahoo Sports - March 4th, 2023 [March 4th, 2023]
- Kyrie Irving and Kevin Durant's trade requests were about seeking control, but also came at a cost for the NBA - Yahoo Sports - February 20th, 2023 [February 20th, 2023]
- 'Winnie-the-Pooh: Blood and Honey' director shares details from the 'unfilmable' first draft of his bonkers horror movie - Yahoo Entertainment - February 18th, 2023 [February 18th, 2023]
- My party of 2 spent $210 to decorate a Mickey Mouse cake at Disney World. It was worth it for the mimosas and desserts alone. - Yahoo Life - February 18th, 2023 [February 18th, 2023]
- Kevin Durant is lone man standing amid Nets mess, and it's time to hit reset before things get uglier - Yahoo Sports - February 7th, 2023 [February 7th, 2023]
- This golden retriever has 'cooked' more than 400 meals. Here's how the dog's human taught him patience in the kitchen. - Yahoo Life - February 7th, 2023 [February 7th, 2023]
- Eagles lineman Brandon Graham fined more than Trent Williams for unsportsmanlike conduct in NFC championship - Yahoo Sports - February 7th, 2023 [February 7th, 2023]
- NASCAR Clash at the Coliseum: Martin Truex Jr. wins chaotic main event ahead of Austin Dillon, Kyle Busch - Yahoo Sports - February 7th, 2023 [February 7th, 2023]
- Kyrie Irving's trade request is logical move to secure his basketball future. Now Nets need to protect theirs - Yahoo Sports - February 5th, 2023 [February 5th, 2023]
- A decade ago, Colin Kaepernick commanded the Super Bowl stage and helped change the QB prototype conversation - Yahoo Sports - February 5th, 2023 [February 5th, 2023]
- M. Night Shyamalan on the 'power' of Bruce Willis, the movie he bet his house on, and his one film people watch on their deathbeds - Yahoo... - February 5th, 2023 [February 5th, 2023]
- Debt limit: Social Security is a hot topic even as the GOP says its off the table - Yahoo Finance - February 5th, 2023 [February 5th, 2023]
- Pamela Anderson's financial woes detailed in new doc: 'On the most famous show in the world' but 'doesn't have a nest egg' - Yahoo Entertainment - February 5th, 2023 [February 5th, 2023]